CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+10.92%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$657M
AUM Growth
+$657M
(-1%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
2.91%
Top 10 Holdings %
Top 10 Hldgs %
66.42%
Holding
38
New
3
Increased
15
Reduced
6
Closed
6
Top Buys
| 1 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$42.8M |
| 2 |
Enliven Therapeutics
ELVN
|
$24.3M |
| 3 |
Vera Therapeutics
VERA
|
$21.9M |
| 4 |
Akero Therapeutics
AKRO
|
$9.68M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$9.19M |
Top Sells
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$32.4M |
| 2 |
Arcellx
ACLX
|
$18.3M |
| 3 |
4D Molecular Therapeutics
FDMT
|
$13.3M |
| 4 |
Aclaris Therapeutics
ACRS
|
$10.1M |
| 5 |
89bio
ETNB
|
$9.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Aclaris Therapeutics
ACRS
$223M
| $5.14M | 0.78% |
635,000
-1,245,286
| -66% | -$10.1M |
|
|
THRD
27
DELISTED
Third Harmonic Bio
THRD
| $4.09M | 0.62% |
993,294
| – | – |
|
28
Adverum Biotechnologies
ADVM
$68.2M
| $3.59M | 0.55% |
+5,000,000
| New | +$3.59M |
|
29
KalVista Pharmaceuticals
KALV
$713M
| $2.46M | 0.37% |
312,553
| – | – |
|
30
Rezolute
RZLT
$630M
| $1.72M | 0.26% |
898,267
-311,733
| -26% | -$599K |
|
31
Acumen Pharmaceuticals
ABOS
$84.2M
| $1.62M | 0.25% |
400,000
-98,315
| -20% | -$399K |
|
|
DBVT
32
DBV Technologies
DBVT
$249M
| $157K | 0.02% |
92,687
| – | – |
|
33
Larimar Therapeutics
LRMR
$337M
| – | – |
-750,000
| Closed | -$3.1M |
|
34
Karyopharm Therapeutics
KPTI
$61.4M
| – | – |
-1,935,609
| Closed | -$6.58M |
|
35
Immunic
IMUX
$79.4M
| – | – |
-1,800,000
| Closed | -$2.52M |
|
|
36
4D Molecular Therapeutics
FDMT
$302M
| – | – |
-598,385
| Closed | -$13.3M |
|
|
37
89bio
ETNB
$1.37B
| – | – |
-758,244
| Closed | -$9.65M |
|
|
38
Arcellx
ACLX
$3.95B
| – | – |
-591,437
| Closed | -$18.3M |
|